FDA Warns RoenRx Over Compounded Semaglutide Labeling and Ozempic Ingredient Claims
On June 8, 2026, FDA issued a warning letter to Roen Health, Inc. dba RoenRx after a March 2026 review of roenrx.com, which offers compounded semaglutide products. FDA says pictured compounded semaglutide products identify "RoenRx" on the label, "suggesting RoenRx is the compounder of those drugs when in fact it is not," and cites claims including "Get affordable semaglutide (main ingredient in Ozempic® & Wegovy®) at an affordable price," noting compounded drugs are not FDA-approved. FDA requested a written response within 15 business days.
What this means"Same active ingredient" marketing can blur the line between an FDA-approved drug and a compounded copy that has never been through FDA review — a distinction worth understanding before ordering through any telehealth platform.
Source: FDA original ↗